Secondary Infections and Mortality in COVID-19

Zhou et al. reported in the Lancet that in 50% of fatal cases a secondary infection which occurred at of median of 17 days. Moreover, 100% of fatal developed sepsis/viremia at a median of 10 days.

Raises the possibility of a strong compensatory anti-inflammatory response/immunoparalysis effect compounded with lymphopenia. Timing of corticosteroids and immunomodulatory therapies are a point of concern.

Curious what type of secondary infections you are seeing (if any) in your ICU?

Lippi and Plebani recommended serial procalcitonin measurement in hospitalized patients with COVID-19, as they found a nearly 5-fold higher risk of severe SARS-CoV-2 infection with an elevated PCT. (

I’m recently retired RN. Forgive me if this has been answered. With hospitals currently incubators of MRSA and C. Diff, why isn’t the COVID patient begun on anti-biotics along with all of the other meds utilized? As I understand it, this virus interacts with bacterium to finish off the immune system.

Thank you to our supporters

Thank you to those that provided an unrestricted educational grant
The Society of Critical Care Medicine (SCCM) is the largest non-profit medical organization dedicated to promoting excellence and consistency in the practice of critical care. With members in more than 100 countries, SCCM is the only organization that represents all professional components of the critical care team. The Society offers a variety of activities that ensures excellence in patient care, education, research and advocacy. Read more
500 Midway Drive, Mount Prospect, IL 60056 USA

Phone: +1 847 827-6888
Fax: +1 847-439-7226
© Society of Critical Care Medicine. All rights reserved.
The Society of Critical Care Medicine, SCCM and Critical Care Congress are registered trademarks of the Society of Critical Care Medicine.
Like SCCM on Facebook  @SCCM on Twitter  SCCM on LinkedIn  Subscribe to the SCCM YouTube Channel  Donate to SCCM